CRC Research Update

  • TRIAL DATA

    Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer

    A Chinese phase III trial of 458 patients with high-risk locally advanced rectal cancer found that integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy (doublet-LC TNT) achieved 3-year disease-free survival of 74.8% compared with 66.0% for conventional neoadjuvant chemoradiotherapy (hazard ratio = 0.674, P = .016). (Journal of Clinical Oncology)

  • RESEARCH

    Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease

    A translational science review in JAMA reports that circulating tumor DNA (ctDNA) sequencing can identify gene variants to inform treatment selection in colorectal cancer, and that detecting ctDNA after curative intent therapy correlates strongly with cancer recurrence and poorer outcomes. (JAMA)

  • LIVING WITH CRC

    Cancer Survivors Face Elevated Risk of Developing Colorectal Cancer

    A Canadian cohort study of 172,928 non-colorectal cancer survivors found they have an elevated risk of developing subsequent primary colorectal cancers compared to the cancer-free population, suggesting tailored screening approaches may benefit this group. (International Journal of Cancer)

  • RESEARCH

    GPR39 Protein Linked to Immunotherapy Resistance in Microsatellite-Stable CRC

    Research using GPR39 knockdown in human and mouse CRC cell lines found that GPR39, a protein overexpressed in colorectal cancer, suppresses ferroptosis (a form of cell death) and reduces the sensitivity of microsatellite-stable tumors to anti-PD-1 immunotherapy. (Canadian Journal of Gastroenterology and Hepatology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

  • Metastatic Colon Cancer Reported in 15-Year-Old Patient

    A case report describes a 15-year-old with metastatic colon adenocarcinoma presenting with abdominal pain, highlighting that colorectal cancer is extremely rare in children and often associated with genetic predisposition syndromes such as Lynch syndrome or familial adenomatous polyposis. (Cureus)

Research continues to advance our understanding of treatment, screening, and resistance mechanisms in colorectal cancer.